SANTA CRUZ BIOTECHNOLOGY, INC.

IL-1F9 (E-13): sc-168163



The Power to Question

BACKGROUND

IL-1 (interleukin-1) is a cytokine responsible for initiating a variety of activities through the activation of transcription factors, NFκB and AP-1, thereby promoting host response to injury or infection. The IL-1 superfamily is comprised of several ligands and receptors. IL-1F9, also known as interleukin-1 family member 9 (IL-1εF9), interleukin-1 homolog 1 (IL-1H1) or interleukin-1 ϵ (IL-1 ϵ), is a secreted ligand belonging to this superfamily. IL-1F9 is highly expressed in skin, stomach, lung and esophagus. IL-1F9 activates the IL-1Rrp2 and IL-1RAcP-dependent pathway leading to NFκB activation. IL-1F5, another member of the IL-1 superfamily, acts as an antagonist, inhibiting the IL-1F9 response. Similar to other family members, IL-1F9 can be regulated by bacterial lipopolysaccharide (LPS). Expression of this protein is stimulated by IFN- γ , TNF α and IL-1 β .

REFERENCES

- Smith, D.E., Renshaw, B.R., Ketchem, R.R., Kubin, M., Garka, K.E. and Sims, J.E. 2000. Four new members expand the interleukin-1 superfamily. J. Biol. Chem. 275: 1169-1175.
- Debets, R., Timans, J.C., Homey, B., Zurawski, S., Sana, T.R., Lo, S., Wagner, J., Edwards, G., Clifford, T., Menon, S., Bazan, J.F. and Kastelein, R.A. 2001. Two novel IL-1 family members, IL-1δ and IL-1ε, function as an antagonist and agonist of NFκB activation through the orphan IL-1 receptor-related protein 2. J. Immunol. 167: 1440-1446.
- Gao, W., Kumar, S., Lotze, M.T., Hanning, C., Robbins, P.D. and Gambotto, A. 2002. Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/ IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J. Immunol. 170: 107-113.
- Berglöf, E., Andre, R., Renshaw, B.R., Allan, S.M., Lawrence, C.B., Rothwell, N.J. and Pinteaux, E. 2003. IL-1Rrp2 expression and IL-1F9 (IL-1H1) actions in brain cells. J. Neuroimmunol. 139: 36-43.
- 5. Towne, J.E., Garka, K.E., Renshaw, B.R., Virca, G.D. and Sims, J.E. 2004. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF κ B and MAPKs. J. Biol. Chem. 279: 13677-13688.
- Vos, J.B., van Sterkenburg, M.A., Rabe, K.F., Schalkwijk, J., Hiemstra, P.S. and Datson, N.A. 2005. Transcriptional response of bronchial epithelial cells to Pseudomonas aeruginosa: identification of early mediators of host defense. Physiol. Genomics 21: 324-336.
- 7. Burger, D., Dayer, J.M., Palmer, G. and Gabay, C. 2006. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract. Res. Clin. Rheumatol. 20: 879-896.
- Barksby, H.E., Lea, S.R., Preshaw, P.M. and Taylor, J.J. 2007. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin. Exp. Immunol. 149: 217-225.

STORAGE

Store at 4° C, **D0 NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

CHROMOSOMAL LOCATION

Genetic locus: II1f9 (mouse) mapping to 2 A3.

SOURCE

IL-1F9 (E-13) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of IL-1F9 of mouse origin.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-168163 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

IL-1F9 (E-13) is recommended for detection of IL-1F9 of mouse and rat origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with other IL-1F family members.

Suitable for use as control antibody for IL-1F9 siRNA (m): sc-146212, IL-1F9 shRNA Plasmid (m): sc-146212-SH and IL-1F9 shRNA (m) Lentiviral Particles: sc-146212-V.

Molecular Weight of IL-1F9: 20 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluo-rescence: use donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.